MDS: Clinical Trials

6 trials for MDS, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed. 6 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 36Completed 6
Phase 21Completed 1

Follow MDS: new trials by email Literature Review of MDS trials Research Report on MDS

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)
APR-246 + azacitidine, Azacitidine - MDS
Phase 3CompletedAprea Therapeutics1542019-01-112025-03-18
Haploidentical Donor vs mMUD in Hematological Malignancies
Peripheral blood stem cells - AML, ALL
Phase 2 / Phase 3CompletedDKMS gemeinnützige GmbH982018-01-012024-08-07
Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML
Decitabine, HYDROXYUREA - MDS
Phase 3CompletedGroupe Francophone des Myelodysplasies1702014-10-142021-11-19
Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Darbepoetin alfa, Placebo - MDS
Phase 3CompletedAmgen1472011-12-212017-12-19
Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts
ON 01910.Na - Myelodysplastic Syndromes, MDS
Phase 3CompletedTraws Pharma, Inc.2992010-11-012020-06-30
Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)
Azacitidine - Leukemia, AML
Phase 3CompletedM.D. Anderson Cancer Center1872009-04-212020-01-14

Narrower conditions

Myelodysplastic Syndromes (3)  ·  Anemia, Refractory, with Excess of Blasts (1)  ·  Leukemia (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Leukemia, Myelomonocytic, Chronic (1)

Broader conditions

Bone Marrow Diseases (3)  ·  Hematologic Diseases (3)  ·  Hemic and Lymphatic Diseases (3)  ·  Leukemia, Myeloid (2)  ·  Neoplasms (2)  ·  Neoplasms by Histologic Type (2)  ·  Anemia (1)  ·  Anemia, Refractory (1)  ·  Chronic Disease (1)  ·  Disease Attributes (1)  ·  Leukemia (1)  ·  Myelodysplastic-Myeloproliferative Diseases (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)

Interventions

Azacitidine (2)  ·  Darbepoetin alfa (1)  ·  Decitabine (1)  ·  Hydroxyurea (1)  ·  ON 01910 (1)  ·  eprenetapopt (1)

Sponsors

Amgen (1)  ·  Aprea Therapeutics (1)  ·  DKMS gemeinnützige GmbH (1)  ·  Groupe Francophone des Myelodysplasies (1)  ·  M.D. Anderson Cancer Center (1)  ·  Traws Pharma, Inc. (1)

Countries

France (4)  ·  Germany (3)  ·  United States (3)  ·  Belgium (2)  ·  Italy (2)  ·  Spain (2)  ·  Austria (1)  ·  Czechia (1)  ·  Greece (1)  ·  Switzerland (1)

Top investigators

David Sallman, MD, PhD (1)  ·  Johannes Schetelig, Prof Dr med (1)  ·  Richard E. Champlin, MD, BS (1)  ·  Steven M. Fruchtman, MD (1)

Results publications

PMID 26968357, PMID 27400247, PMID 33170934, PMID 33513373, PMID 36455187

NIH funding

2009 (1), 2015 (1)